/HSCTMGD

Wenxin Zhao1, Xiaohui Luo2, Jing Yang2

  • 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China; Department of Ophthalmology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

概括

梅博米腺功能障碍 (MGD) 可能不会改善,即使在异构造血细胞干细胞移植 (allo-HSCT) 后慢性眼球移植与宿主疾病 (coGVHD) 的严重程度降低. 停止或减少免疫抑制剂与MGD恶化有关.